Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to equity ratio is 0.00 as of the fiscal period ended Friday, July 31, 2026.
Reported quarterly debt to equity ratio; no daily interpolation. Q1 FY2027 (2026-07-31): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
0.00
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
0.00
DEBT TO EQUITY RATIO AVG 10Y
0.01
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
-100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 470 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Alzamend Neuro Inc
Market Cap
$5.40M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$5.33M
Debt to Equity Ratio
N/A
TTM Avg
0.07
3Y Avg
0.07
5Y Avg
0.07
Market Cap
$5.31M
Debt to Equity Ratio
4.80
TTM Avg
6.38
3Y Avg
6.38
5Y Avg
6.38
Market Cap
$5.47M
Debt to Equity Ratio
0.33
TTM Avg
0.21
3Y Avg
0.27
5Y Avg
0.18
Market Cap
$5.59M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$5.01M
Debt to Equity Ratio
1.57
TTM Avg
0.64
3Y Avg
1.33
5Y Avg
1.33
Market Cap
$5.97M
Debt to Equity Ratio
0.10
TTM Avg
0.10
3Y Avg
0.10
5Y Avg
0.10
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alzamend Neuro Inc (ALZN) | $5.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| Lunai Bioworks Inc. (LNAI)vs › | $5.33M | N/A | 0.07 | 0.07 | 0.07 |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.31M | 4.80 | 6.38 | 6.38 | 6.38 |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.47M | 0.33 | 0.21 | 0.27 | 0.18 |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.59M | 0.00 | 0.00 | 0.00 | 0.00 |
| Imunon, Inc. (IMNN)vs › | $5.38M | 1.87 | 0.21 | 0.18 | 0.20 |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.01M | 1.57 | 0.64 | 1.33 | 1.33 |
| Lucyd, Inc (LUCY)vs › | $5.83M | 0.01 | 0.00 | 0.01 | 0.28 |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.97M | 0.10 | 0.10 | 0.10 | 0.10 |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.84M | 0.36 | 0.26 | 0.18 | 0.25 |
Debt/Equity
0.00
Current Ratio
3.01
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-07-31 | 0.00 |
| 2026-04-30 | 0.00 |
| 2026-01-31 | 0.00 |
| 2025-10-31 | 0.00 |
| 2025-07-31 | 0.00 |
| 2025-04-30 | 0.00 |
| 2025-01-31 | 0.00 |
| 2024-10-31 | 0.00 |
| 2024-07-31 | 0.00 |
| 2024-04-30 | -0.12 |
| 2024-01-31 | -0.11 |
| 2023-10-31 | 0.00 |
| 2023-07-31 | 0.00 |
| 2023-04-30 | 0.00 |
| 2023-01-31 | 0.00 |
| 2022-10-31 | 0.00 |
| 2022-07-31 | 0.00 |
| 2022-04-30 | 0.00 |
| 2022-01-31 | 0.00 |
| 2021-10-31 | 0.03 |
| 2021-07-31 | 0.02 |
| 2021-04-30 | 0.17 |
| 2021-01-31 | -0.94 |
| 2020-10-31 | 0.00 |
| 2020-07-31 | 0.00 |
| 2020-04-30 | 0.08 |
| 2020-01-31 | 0.00 |
| 2019-10-31 | 0.04 |
| 2019-07-31 | 0.04 |
| 2019-04-30 | 0.25 |
| 2019-01-31 | 0.25 |
| 2018-10-31 | 0.04 |
| 2018-07-31 | 0.04 |
| 2018-04-30 | 0.00 |
| 2018-01-31 | 0.00 |
| 2017-10-31 | -5.75 |
| 2017-07-31 | -5.75 |
| 2017-04-30 | -1.01 |
| 2017-01-31 | -1.01 |
| 2016-10-31 | 0.16 |
| 2016-07-31 | 0.16 |
